Official Website: Sethera Therapeutics

Summary

Sethera Therapeutics' official website describes an enzymatic peptide cross-linking platform for synthesizing stable polymacrocyclic peptides (pMCPs), with partner-facing discovery capabilities and a Salt Lake City office.

Useful Claims

• The site positions Sethera around enzymatic peptide cross-linking technology for stable, polymacrocyclic peptide therapeutics.
• Sethera offers a PolyMacrocyclic peptide (pMCP) Discovery Platform for partners to discover and engineer macrocyclic peptides with diverse architectures and chemistries.
• Platform capabilities described include enzymatic library creation, hit identification, tuning with noncanonical building blocks, and modular polymacrocyclic recombination.
• The cyclization enzyme is said to recognize programmable sequence motifs to site-specifically install thioether bonds, potentially multiple times per molecule.
• The approach is described as compatible with phage, mRNA display, and DNA-encoded library screening methods.
• Sethera states it is seeking partners to leverage its peptide architectures for target screening and drug discovery collaborations.
• Office address listed: 48 S Rio Grande St, Salt Lake City, UT 84101.

Verbatim

"Sethera is revolutionizing peptide-based drug development with our cutting-edge enzymatic cross-linking technology." — Home page, company description

"Sethera has a PolyMacrocyclic peptide (pMCP) Discovery Platform that helps partners discover and engineer MCPs with unique architectures and chemistries for targets of all kinds." — Home page, platform description

"Our cyclization enzyme recognizes programmable sequence motifs to site-specifically install a thioether bond. It can do so multiple times in a single molecule, building diverse macrocycle architectures as small as just 7 atoms, or as large as 13 amino acids– with up to 6 macrocycles per peptide." — Home page, “Innovations & Vision”

"The approach works seamlessly with today’s top macrocycle screening techniques, including phage, mRNA display, and DNA-encoded libraries." — Home page, screening compatibility

"Sethera Therapeutics is seeking partners interested in leveraging our peptide architectures to screen their biological targets." — Home page, partnerships

"Sethera Therapeutics 48 S Rio Grande St Salt Lake City, UT 84101" — Home page, office

Reliability Notes

This is an official company source. It is useful for platform positioning, enzymatic-mechanism claims, and partnership intent, but generalization across peptide targets, clinical-candidate status, and in-vivo validation should be cross-checked with peer-reviewed publications and independent technical sources before being treated as high-confidence evidence.

Related Pages

• Sethera Therapeutics

See Also

• Sethera team page · https://setheratx.com/sethera-team/ — leadership and advisory board listed on the official site